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Abstract 
The declining cost of DNA sequencing has been accompanied by a proliferation of 
companies selling “direct-to-consumer-genetic-testing” services (DTC-GT). Many of these 
are marketed online as tools for enabling citizens to make more informed decisions about 
their health, wellness and lifestyle. We assessed the ‘information for consumers’ provided 
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by these companies at the pre-purchase stage, which could influence initial decisions to part 
with money, data or tissue samples. 
A scoping exercise revealed 65 DTC-GT companies advertising their services online to 
consumers in the United Kingdom (UK), of which 15 met our inclusion criteria. We 
benchmarked their consumer information against the good practice principles developed by 
the UK Human Genetics Commission (HGC).  
No provider complied with all the HGC principles and overall levels of compliance varied 
considerably. While consent for testing was discussed by all but one company, information 
about data reuse for research or other purposes was often sparse and consent options 
limited or unclear. Most did not provide supplementary support services to help users 
better understand or cope with the implications of test results.  
We provide recommendations for updating the pre-consumer transparency aspects of the 
HGC guidelines to ensure their fitness-for-purpose in this rapidly changing market. We also 
recommend improving coordination between relevant governance bodies to ensure 
minimum standards of transparency, quality and accountability. While DTC-GT has many 
potential benefits, close partnership between consumers, industry and government, along 
with interdisciplinary science input, are essential to ensure these innovations are used 
ethically and responsibly.  
(242 words) 
 
Introduction 
New DNA sequencing technology has spawned a growing market in genetic testing services 
sold directly to members of the public (1, 2), rather than being ordered by a clinician for 
medical reasons (3). These direct-to-consumer-genetic-tests (DTC-GT) are being marketed 
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online, promising purchasers insights about their ancestral past, present states e.g. being 
overweight, future risks ranging from premature balding to cancer, or even their own or 
their child’s potential for intellectual or sporting achievement (4, 5). Health, wellness and 
lifestyle related services represent an important sub-sector of this market. While most are 
not strictly ‘medical’, many vendors of such services claim that these can empower 
consumers to make better health decisions by highlighting aspects of their genetic make-up 
that could affect their clinical risks or mediate the influence of lifestyle factors, medicines, 
nutritional choices or fitness regimes (6).  
Although an exciting idea, DTC-GT comes with many uncertainties and challenges and given 
the psychosocial and privacy implications of genetic test results, it can represent a source of 
personal and societal risk. There is still limited evidence of the clinical utility of some of 
these tests, despite other types of personal and social value which purchasers may derive 
from them (3).  Importantly, the extent to which consumers understand what they are 
buying, how they understand the results, what behaviours these trigger, and what will 
happen with their genetic information after the transaction, is still lacking (7, 8). Despite this 
uncertainty, governance of this rapidly diversifying sector has been hobbled by the 
multiplicity of bodies potentially involved in their oversight or regulation (Figure 1). For 
example, concerns about such products and services can span in-vitro medical device safety, 
consumer rights, fair advertising and data protection (9-12). To compound this, services sold 
online in one country may be underpinned by operations located in other regions with 
different regulatory jurisdictions, making it difficult for consumers to easily judge their rights 
for protection and recourse. Mindful of liability risks, many DTC-GT companies are 
marketing their services as “information products” rather than medical products, with the 
intent of them being “for educational purposes only” and stipulate that the test results are 
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not for diagnostic use. In the UK the DTC-GT industry is minimally regulated. Due to this 
lightweight governance, healthcare practitioners and professional bodies such as the 
Association for Molecular Pathology (13), the European Society for Human Genetics (14) 
and the American College of Medical Genetics and Genomics (15), have called for further 
guidelines and standards and have released their own (sometimes conflicting) guidance. In 
addition, consumer rights groups such as GeneWatch UK are becoming more vocal (16). 
Concerns have also been raised about the scientific integrity and clinical utility of some DTC-
GT services, particularly those based on Genome Wide Association Studies (GWAS), which 
tend to have low discriminatory and predictive validity (17). The transparency of providers’ 
activities has also been called into question relating to quality criteria and quality assurance 
(18). Although some guidelines cover scientific considerations, e.g. how to communicate the 
strength of evidence underpinning various genetic predictions (19), consistent global 
industry standards for transparency in the DTC-GT sector do not currently exist (11). 
Importantly, aside from scientific and clinical considerations, the ethical principles such as 
transparency, accountability and accessibility and choices and the quality of companies 
supporting information for customers is largely unchecked; a situation which has drawn 
attention from policymakers (20) and the biomedical industry itself (21).  
In the United Kingdom companies are permitted to provide DTC-GT services to members of 
the public (22). Mindful of this, the UK government established a working group as part of 
the Human Genetics Commission (HGC), to advise on ethical practices within the industry. 
This included multidisciplinary stakeholders such as medical doctors, scientists, lawyers, 
professional organizations, government, and a company that was offering DTC-GT (deCODE 
Genetics) (23, 24). The HGC’s ‘Common Framework of Principles for DTC-GT’ were released 
in 2010, and remain the only multi-stakeholder developed consensus guidelines focused on 
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best practice in DTC-GT in the UK. Significantly, the HGC’s framework included specific 
recommendations relating to pre-purchase ‘information for consumers’ which are 
particularly useful for benchmarking the transparency of DTC-GT companies, as is the focus 
of this study. Although other relevant guidelines have since been released by single 
stakeholder groups such as medical genetics professionals like the European Society of 
Human Genetics they do not cover issues of transparency or pre-purchase information in 
depth. For the purposes of our analysis we therefore selected the key HGC principles 
relating to ‘information for consumers’ and sought to identify to what extent these 
recommended practices have been adopted by the sector, thereby assessing the 
responsiveness of the industry in adopting best practice standards (25). 
 
Methods 
We searched for companies actively advertising to UK consumers for health, lifestyle and 
wellness related DTC-GT through Google UK searches, using the keywords “genetic testing”, 
“health”,” wellness” and” lifestyle”. For the purposes of the study we defined active 
advertising in terms of companies’ appearance in the first five pages of an online search on 
google.co.uk or appearing via “google ads”. We acknowledge the variability in search engine 
results and so during the search process, we also identified a commercial website where 
DTC-GT companies pay to advertise and list their services to UK consumers (26), which we 
used to verify and supplement our findings. Of the companies identified by these searches, 
we selected only those offering DNA testing for health, lifestyle and wellness and excluded 
companies offering neonatal services or only performing ancestry or paternity testing, or 
not actively trading; for example, a telomere testing service that was described as “coming 
soon”. Additionally, by default, we excluded private medical services where tests are 
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recommended by a clinician, focusing our attention only on those services that consumers 
can order directly online. The search took place between January 15th and June 30th, 2016. 
 
To assess the transparency of information available to consumers at the pre-purchase stage, 
we extracted key documents from companies’ websites for review. The target documents 
included Terms of Service (ToS), privacy statements, Frequently Asked Questions (FAQ) and 
informed consent documents, where available online. One company also had a “Code of 
Practice” statement, which we included. We worked on the principle that all the necessary 
key information should be presented openly to potential purchasers in these documents, 
without them having to search each website extensively for fragments of information or 
wait until after ordering the service. 
We created an initial checklist of assessment questions consisting of 16 key criteria derived 
from the section of the HGC guidelines concerning “Information for prospective consumers”. 
A pilot review assessed the applicability of the checklist to current DTC-GT provider 
practices (27). During this process, an additional 12 questions were added to the checklist, 
in most cases consisting of more detailed sub-questions associated with a broader item 
from the original HGC recommendations (see Supplementary Information SI Table 1 for 
details).  
In the second phase, we moved to a full assessment, involving three evaluators; an expert in 
biomarkers and quality assessment (JH) a specialist in health information governance and 
data protection (RG) and two solicitors specializing in ethical practice (DD and SF, providing 
a single rating sheet). A training process for assessors took place to ensure common 
interpretation of the language and concepts used in the criteria and resolve ambiguities in 
advance of the task. The detailed assessment exercise took place between February and 
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June 2016. For each criterion, the available information was classified as “Addressed”, “Not 
Addressed” or “Not Applicable”. Inconsistencies were resolved through discussion and, 
where necessary, arbitrated by a fourth independent evaluator (CP). 
Results 
65 companies were identified from the broad search. These companies offered a range of 
services within the broad categories of ancestry, paternity testing, neonatal testing, beauty 
(skincare) and ageing (telomere testing), as well as health, wellness and lifestyle. Out of 
these we selected those offering DNA testing in health, lifestyle and wellness (N=15), as per 
our inclusion criteria, meaning that 50 were eliminated from our review. The 15 remaining 
companies encompassed services prioritising physical fitness, nutrition and health-related 
wellness, lifestyle and phenotypic traits, in addition to those concerned with disease 
susceptibility, drug sensitivity, disease prevention and disease risk assessment (Table 1). 
The 15 DTC-GT providers selected offered a diversity of services within the test categories 
presented in the Supplementary Information as defined in the HGC guidelines, ranging from 
pre-symptomatic tests, carrier testing, testing for disease susceptibility traits, 
pharmacogenetics, nutrigenetics and lifestyle/behavioural traits. Some providers focused on 
one or two types of service whereas others covered these categories. For example, only 
3/15 services included carrier testing whilst 13/15 companies offered testing for 
nutrigenetic and lifestyle/behavioural traits testing (Table 1). 
Only 10/15 eligible companies were registered in the UK. Others were registered elsewhere 
but were nevertheless attempting to engage with UK consumers. In some cases, it was 
difficult to identify the origins of the company based on the information provided on their 
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consumer-facing website; for example, language such as “principal place of business” was 
used ambiguously. 
Not all companies provided similar documentation such as ToS and privacy statements, FAQ 
or informed consent templates. In some cases, these were referred to using different words 
or combined within the same document. For example, some companies embedded 
informed consent statements within their ToS or privacy statements, while others supplied 
separate detailed informed consent forms. Additionally, one company had a “Code of 
Practice” statement and one had a separate “Family Considerations” document as well as a 
separate “Biobank” consent form. 
All reviewers remarked on both the variability of the reviewed documents’ format and 
content. Reviewers noted that, in some cases, the term ‘genetic data’ was not defined, 
there was little or no information about genetics or risks specific to genetics. Also, that the 
scope of testing performed was not always adequately explained and no assurances were 
given that further testing would not take place for purposes beyond those for which the test 
was purchased. 
Overall compliance with HGC principles 
As illustrated in Figure 3, none of the DTC-GT companies reviewed complied with every HGC 
recommendation. There did not appear to be any clear differences in the providers’ 
tendency to comply with the HGC criteria depending on whether the type of service 
emphasised health-related traits (e.g. carrier status, drug sensitivity, inherited conditions) or 
lifestyle and wellness factors (e.g. diet, weight-loss, nutrition and fitness related traits) and 
for this reason we have not presented a separated analysis.  
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Some criteria were widely met by the companies in the sample and others hardly at all. 
Table 2 summarises the most and least frequently adhered-with principles (the full list of 
criteria used are provided in the Supplementary Information). An important differentiating 
factor between DTC-GT providers, was the extent to which they were explicit about the 
ways in which they protected users’ information, their intended future uses of customers’ 
data and the options available for differential consent of withdrawal. These considerations 
are the focus of the section below. 
Consent for genetic testing 
A key ethical principle specified by HGC is that patients should be required to give informed 
consent for genetic tests to be undertaken. Most companies (14/15) followed at least one of 
the following three themes. These themes were identified in the reviewer’s discussion: 
Theme A, the company explicitly stated in their ToS or Privacy Statement that informed 
consent was required before testing. 7/15 stated that customers would be asked to sign a 
separate informed consent document (for example after receiving the kit) if they wished to 
proceed with the test. Only 1 provided the informed consent document on their webpage, 
while 1 provided their informed consent document upon request (by email).  Theme B the 
copany mentioned consent within their ToS or privacy statements, indicating that if the 
consumer agreed with these then they would be assumed to have given informed consent 
for testing (5/15). This did not require ticking a separate box. For example, “You 
acknowledge that by agreeing to the terms of this privacy statement when purchasing 
services on this site, you are giving us your explicit consent to process this sensitive personal 
data related to you.” Or “By proceeding with any test you are formally providing your 
informed consent to undergo a specific test”. 
Theme C, the company included statements to say, “we shall not process any data without 
 10
your consent” but did not specify what the consent process involved (2/15). 
One company (1/15) neither mentioned the requirement for informed consent nor provided 
an informed consent form, in the pre-purchase documentation we reviewed. Therefore, the 
rigour and transparency of the consent processes provided by companies were highly 
variable. 
Consent for reuse of genetic data 
Only 4 companies explicitly discussed the re-use of customers’ genetic data for research 
suing specific and defined terminology, but they did so with varying levels of transparency. 
One company explicitly defined “aggregate data” as different from “individual level” genetic 
data and stated that it automatically shared “aggregate” genetic data for research if the 
service was purchased, but required a separate informed consent for the use of “individual 
level” genetic data in research. Another 3 companies stated that "anonymised” genetic data 
would be shared for research without defining what “anonymised” meant. Of these three, 
only one explicitly sought separate informed consent to share this data for research through 
an opt-in mechanism (as recommended by the HGC), while the other 2 automatically shared 
de-identified genetic data in research if the service was purchased. A fifth company simply 
claimed ownership of customers’ data, but gave no specific information about how this 
might be used. Some companies made no specific reference to secondary uses of the 
genetic data, making it impossible to judge their policies or practise in this regard. The 
variability in approach between companies was marked, those providing detailed 
information boosted confidence in their service offering and companies offering no 
information appeared weak in comparison. 
Withdrawal of consent/cancellation of service 
Only one company was explicit about the consequences of withdrawing from the testing 
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service, including what would happen to customers’ genetic data upon account closure. This 
company’s information clearly differentiated withdrawal from the testing service and 
withdrawal of consent for future uses of data in research, thereby allowing consumers to 
retain the testing service account even if they decided to withdraw from research. The 
remaining companies were much less clear on this point; some discussed the possibility of 
closing your account or if you no longer wanted to use the service, but were not clear on 
what would happen to the genetic data. Several (6/15) companies mentioned the right to 
cancel the purchase and offered a cooling off period, but did not discuss what would 
happen to any genetic data that may have been generated prior to cancellation. The 
distinction between the right to cancel a service (cooling off period) and the right to 
withdraw after participating in testing should be made clearer and both options should be 
available to the consumer. 
Client confidentiality and data protection 
Although many providers (9/15) referred to data protection law(s) applying to their service, 
only one company explicitly stated that it was registered with the UK Information 
Commissioner’s Office as a data controller. Many gave general statements such as “we shall 
not use or process your data without your consent”. Furthermore, as some companies 
spanned operations in several jurisdictions, a variety of laws governing uses of customers’ 
tissue samples and genetic data were mentioned, with potential to confuse consumers as to 
their rights and confidentiality. 
Test accuracy and scope 
In the UK, and approximately 60 other countries, ISO15189 is the current standard for 
accreditation of laboratories that perform medical genetic tests, and ISO15189 states 
laboratories should participate in regular External Quality Assessment (EQA), to ensure the 
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accuracy of their test results. However, for companies offering DCT-GT for “information and 
educational purposes only” there is no requirement for ISO15189 accreditation (and thus 
participation in EQA), although this does not prevent them from voluntarily conforming with 
ISO standards and participating in EQA. A second quality indicator is the CE-mark, a well-
known symbol designed to enable consumers to verify the quality and safety of products in 
the EU. The CE-mark is required for diagnostic kits under the EU In Vitro Diagnostic Medical 
Device regulation. In the UK, the CE-mark is given by the Medicines and Healthcare Products 
Regulatory Agency (MHRA), the body responsible for ensuring that medical diagnostic tests 
reach these standards in the UK. Some DTC-GT services do fall under the remit of the CE-
mark, even if the DTC-GT service provided is informational rather than medical diagnostic 
testing. However, MHRA only reviews services related to testing for disease and disease risk, 
thus genetic testing for nutrition, lifestyle and behavioural traits - representing a large 
section of the current market – is not covered under this remit. Moreover, the assessment 
required for the CE-mark only covers the testing kit/ technology and not other aspects of 
the service such as the quality of consumer information, transparency or data protection.  
We analysed companies’ consumer pre-purchase information relating to these three points 
(ISO accreditation, participation in EQA and CE-marking). Relatively few companies 
mentioned the accreditation of the laboratories used, or indicated why this might be 
relevant. Two companies referred to ISO17025; a standard for accrediting laboratories’ 
which is not widely recognised as the standard for medical testing in the UK or EU; and one 
referenced Clinical Pathology Accreditation (CPA); which has been phased out since 2009. 
One referred to AABB accreditation (standards of transfusion medicine and cellular 
therapies to optimize patient and donor care and safety) which appeared irrelevant to the 
DTC-GT service, and one referred to the Care Quality Commission without specifying how 
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this applied to their service. Only one company mentioned ISO15189 accreditation of the 
laboratory used, which appeared to be specific to the BRCA1/BRCA2 testing service. This 
provider also mentioned participation in a recent, relevant, EQA scheme. One company 
referred to CLIA, the US-standard for clinical laboratory testing however CLIA does not 
require the same level of depth as ISO15189, the latter requiring more depth on quality 
management, the establishment of continual quality improvement, and true audit-based 
monitoring. No other companies mentioned participation in EQA schemes. 
Whilst the MHRA recommends that consumers search for the CE-mark associated with DTG-
GT kits when purchasing products (28), none of the companies mentioned CE-marking in 
their pre-purchase information. This is not to say that some companies did not have CE-
marking but rather that this information was not provided within their pre-purchase 
information, despite its possible influence on consumers’ decisions. 
Although some companies referred to laboratory accreditation, as described above, all 
companies included disclaimers in their consumer information, stating that they offered no 
guarantee of the quality of their laboratory results. Most also stated that the tests were not 
for diagnostic use and were for information and educational purposes only. The lack of 
information of these quality indicators, or mention of accreditation that seemed irrelevant 
could lead the educated reader to a sense of distrust in the quality services offered. Greater 
efforts must be made to address these quality concerns in this field. 
Pre and Post-Test Genetic Counselling and Expert Advice  
The HGC recommends that genetic counselling should accompany any genetic tests “in the 
context of inherited or heritable disorders”. Three out of the 15 services we reviewed 
included tests relating to carrier status of heritable disorders but only 2 offered post-test 
genetic counselling. In addition to inherited disorders, test results for health, lifestyle and 
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wellness factors can also be confusing for purchasers or may suggest lifestyle changes for 
which expert advice in the form of a face to face or telephone consultation with an expert 
may be beneficial. We extended this principle of a consultation to encompass all types of 
test and expert council (nutrition, fitness, drug sensitivity etc.), most companies (9/15) did 
not specify that customers would have an opportunity to speak to a counsellor or trained 
expert as part of their standard service. 4 companies offered an optional pre-test 
consultation and 6 a post-test consultation. Post-test consultation was offered as an 
optional service to purchase in half of these cases. Even those services that performed best 
in the overall assessment of best practice fell short on this criterion and, overall, there was 
no obvious trend for more counselling to be offered by companies meeting more HGC 
criteria. An open discussion needs to be had with the industry about minimum standards of 
diligence in conveying information back to consumers, that also extends beyond hereditary 
disease situations. 
Formal Complaints Process 
Across all the companies reviewed, there was a consistent lack of information for 
consumers regarding a formal complaints process. Only 3/15 companies provided some 
information about a complaints process and one of those stated that “all decisions of the 
management are final”. There was a lack of reference to any external body to which 
complaints could be made if the consumer was not satisfied, most likely because there is no 
overarching body currently in place that could fulfil this role. 
Discussion 
The HGC published its principles and recommendations in 2010, with a view to guiding 
companies active in or entering the DTC-GT space. This remains the only available set of 
guidelines that has been developed by representatives of all major stakeholders, including 
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industry members and regulatory bodies.  While other guidelines exist, these typically 
represent the viewpoints of single organisations, such as those representing healthcare 
professionals. 
The company that contributed to the HGC committee is no longer a provider of DTC-GT and 
none of the companies reviewed in this study participated in writing the HGC principles, 
indeed most did not exist at that time.  This illustrates the growing disconnect between the 
sector offering services and the existing guidance, which is not fully addressed by newer 
academic guidelines developed by individual stakeholder groups (13,14,15).  
Our analysis shows that none of the vendors actively targeting UK consumers comply fully 
with the HGC principles and the industry has not so far embraced the self-regulatory 
approach that was envisaged at the time these were developed. Adherence with individual 
HGC criteria is typically inadequate and varies widely. The information provided to 
prospective purchasers is, in many cases, lacking in detail or unclearly worded, and the 
stated ToS can be ambiguous. Even those companies that performed best overall in our 
assessment fell short on the provision of counselling or expert advice as part of their service 
or even as an add-on. One company stated its own best practice criteria (‘code of practice’) 
on its website, without any reference to these being grounded in any external guidance 
(29), suggesting that while the sector is beginning to recognize the need for ethical and 
quality standards there is still an absence of consensus on a single set of accepted criteria. 
We also identified aspects of the existing HGC guidance that require updating or extension 
to meet the needs of this rapidly evolving market; a greater emphasis on the transparency 
of vendors’ ToS and privacy statements with respect to the products and services offered 
and the future uses of customers’ data, distinction of cancellation of the service vs 
withdrawal from data (re)use, formal complaints processes and more explicit and specific 
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consent processes. Companies need to better address the language used to describe genetic 
data; indeed 7/15 companies did not even specify “genetic” or “DNA” when referring to 
data in their ToS and privacy statements but simply talked about “your personal data”. 
Greater specification of the accuracy and reliability of tests used, and their ability to be used 
in medical decision making, alongside references to appropriate and current quality 
standards, such as laboratory accreditation, participation in proficiency testing and CE-
marking (where applicable) are also needed to help consumers make informed purchasing 
decisions. A lack of counselling or an opportunity to discuss test results with an expert also 
represents an important weakness in this sector, given the expertise required to properly 
interpret test results and the fact that some results may lead to anxiety for consumers. 
While a few companies offer a personalized consultation as part of their service, some 
either sell it as an extra service or make recommendations on how to obtain it, but many 
simply do not mention this as an option in their consumer-facing documents. These deficits 
in information and counselling may help to explain the results of recent research indicating 
that DTG-GT can leave consumers more confused about their health, rather than more 
enabled to manage it effectively (30). Nevertheless, the mere involvement of a physician is 
no guarantee of good practice; indeed, a recent review identified poor consent mechanisms 
in several companies whose services could only be ordered through a physician (31) and in 
our review the company with the worst overall rating for transparency had medical doctors 
available for post-testing counselling. 
While we made efforts to identify all companies selling DTC-GT services to UK consumers in 
the areas of ‘health, wellness and lifestyle’, this review must be regarded as a snapshot of a 
rapidly evolving market that deserves ongoing monitoring and governance. At this time, no 
single government body or professional association fulfils this oversight role in the UK.  
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Our analysis focused only on the online documentation offered by vendors to potential 
customers at the pre-purchase stage, which may influence their decisions to part with 
money, tissue samples or personal data (Figure 3). We looked specifically at the documents 
relating to fair marketing such as quality of service, data protection, consumer safety, 
transparency and accountability. We acknowledge that vendors may provide additional 
information elsewhere, such as on separate protected websites available post-purchase or 
in paper documents provided alongside test kits, however our perspective was that key 
information should be available ‘front-of-house’ in an accessible and central form, even if 
repeated elsewhere, in order to support informed choice at the point of sale. Arguably, the 
transparency and usefulness of this information may also indicate companies’ broader 
philosophies, experience, and management practices, although we leave this for others to 
unpack through a more in-depth analysis of purchased products and services. 
Our emphasis on the HGC guidelines was driven by our focus, for the purposes of this study, 
on UK consumers and the UK market, given the time elapsed since the HGC was disbanded 
and our awareness of the complex and somewhat disjointed state of UK regulation, which 
spans multiple bodies and relies heavily on industry self-governance (Figure 4). This 
fragmentation has also been described in a recent systematic review of European 
guidelines, recommendations and position statements (12). Our assessment was based on a 
simple, actionable, yes/no checklist. We did not specifically examine the fitness-for-purpose 
of contract language relevant to the HGC principles and this would merit further study. Our 
interdisciplinary team nevertheless included experts in genetics, laboratory testing 
standards, eHealth, consumer rights law, information governance and bioethics. As our 
review included companies offering a range of health-related, wellness, fitness, testing 
services we were able to compare across sectors of the market, however no major 
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differences in HGC compliance between these types of company were discernible from our 
analysis, although we acknowledge the relatively small study size. 
Our results are consistent with a recent review of the United States’ DTC-GT market, which 
also revealed inconsistent provision of information regarding security protocols and tissue 
retention, along with significant gaps around transparency, readability and informed 
consent processes for the reuse of data and tissue samples in research, despite most 
companies posting privacy statements (31). In addition to DTC-GT companies transacting 
solely with consumers, those involving physicians can also exhibit poor practices. For 
example, in our study the DTC-GT company that performed worst on the HGC-derived 
transparency criterion had medical doctors both on the management board and providing in 
post-testing counselling as part of the service, whilst in the US study two out of the three 
companies failing to seek consent for research uses of customers’ data or samples also 
explicitly required physicians to be involved in ordering the service (31). 
Conclusions and recommendations 
Companies selling genetic tests directly to the public are proliferating in both number and 
diversity and are becoming increasingly popular with consumers seeking to understand or 
optimise their current and future health and wellbeing. Given the psychosocial and privacy 
implications of genetic test results, and their potential use by insurers, they also represent a 
source of personal and societal risk. Alongside the decreasing costs of genome sequencing 
the value of the DTC-GT sector has been projected to reach a $340M by 2022 (32, 33), which 
may tempt some businesses to be less stringent with their offerings to reach lucrative 
markets of both direct citizen consumers and indirect consumers, such as commercial data 
brokers. However, companies which fail to innovate ethically and responsibly not only 
damage public trust but are also at commercial risk, if tougher penalties are being levied on 
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those that fail to comply with appropriate regulations (34). For this reason, standards for 
quality, transparency and accountability will prove increasingly essential, both for consumer 
protection and for the sustainability of this business sector. 
Our study reveals that over the last 6 years since the HGC principles were released in the 
UK, self-regulation of DTC-GT in the UK has not led to consistent quality and transparency 
for consumers, with uptake of the HGC principles being inadequate and patchy. This leads 
us to question the efficacy of the current self-regulatory approach, which also reflects the 
absence of an integrated oversight body for DTC-GT in the UK, where relevant 
responsibilities are currently distributed across multiple agencies.  
Although the HGC guidelines remain valuable for informing best practice they require 
updating to account for industry trends, including not only the proliferation of DTC-GT 
companies but also the diversification of their products and services, as well as emerging 
business practices such as the harvesting of customers’ data for further research or re-sale, 
which threaten to compromise privacy and personal control. Given that DTC-GT are typically 
sold online, single-nation approaches are unlikely to be sufficient and global governance 
mechanisms with proactive oversight and regulatory alignment, are needed to protect 
consumers, maintain public trust and drive quality standards in the industry. This is a 
challenging prospect and our study demonstrates the difficulty of achieving this in one 
country alone. In this respect, it has been observed that numerous European policy reports 
on DTC-GT have been written but few have been implemented (12). 
We recommend new efforts to agree minimum standards of transparency and quality, with 
appropriate mechanisms of review and certification of DTC-GT providers to increase the 
accountability of companies active in the DTC-GT market. Providing an independent trusted 
quality mark would benefit both consumers and healthcare professionals dealing with 
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questions from patients who have purchased or are thinking of purchasing DTC-GT services 
(35).  
The results of our study have shone a light on inadequacy of the pre-purchase information 
currently being provided to UK consumers by DC-GT companies and its inconsistencies with 
the principles for good practice laid out by the HGC. Our suggestions for improving 
transparency and consumer support, decreasing risk and improving governance add to 
others in the literature and are compatible with several ongoing developments such as the 
EuroGenTest tool, which has been designed to aid professionals and consumers through 
choices about purchasing DTC-GT (36).   While there is clearly a need to improve the 
transparency, quality and accountability of DTC-GT companies operating in the UK, in this 
global service market laboratories and business operations may be distributed across 
jurisdictions and greater international collaboration is also needed to agree consistent and 
actionable standards and mechanisms of governance. 
While DTC-GT offers opportunities for consumers to better understand and manage their 
personal health and wellness, industry self-regulation has failed to ensure compliance with 
best practice and the transparency of the information available to guide consumers’ 
purchasing decisions falls short on many criteria. Improving transparency, quality and 
accountability in this fast-evolving sector is essential to protect consumers and ensure 
responsible innovation and business practices. Achieving this will require partnership 
between citizens, industry and government, alongside interdisciplinary science input. As a 
first measure, we suggest revisiting and updating the 2010 HGC guidelines in the UK to take 
account of innovations and changes in this market and to create a specific set of criteria on 
transparency. We also recommend greater dialogue between the various stakeholders, 
including the companies, as well as increased coordination between regulatory bodies 
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concerned with consumer genetic testing, such as regulators of medical devices, consumer 
safety, data protection and fair marketing, to address their gaps and misalignments.  In this 
global market, new initiatives to seek wider agreements on international standards for 
quality, transparency and certification are also called for. 
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Titles to legends and figures 
Figure 1. A schematic of the relevant governance bodies that touch upon aspects of DTC-GT 
services. Broken lines indicate bodies that could be involved in regulating DTC-GT but that 
currently do not play a dedicated role in regulating DTC-GT. 
Figure 2. A heatmap of the companies’ adherence with the items on the HGC-derived 
checklist, based on the information disclosed to consumers at the pre-purchase stage. Panel 
A indicates congruence with individual HGC criteria (indicated with *) and additional criteria, 
and panel B indicates whether consultation with a specialist (genetic counsellor or trained 
expert) was provided as part of the service. The rows represent criteria and the columns the 
DTC-GT providers reviewed. 
Figure 3. A schematic of the stages in the DTC-GT pathway, including relevant consumer 
issues, exit points and relevant governance bodies.  
Table 1. Study flow chart. Note that some companies cover more than one area of testing 
services.  
Table 2. Illustration of the most and least frequently adhered-with principles. 
Supplementary information is available at European Journal of Human Genetics’ website 
(Supplementary Information SI Table 1). 
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Table 1.  
 
 
 
  
DTC-GT companies marketing to UK 
consumers (N=65) 
Selection of DTC-GT companies: Health, 
lifestyle & wellness (N=15) 
• Nutri-genetic & lifestyle traits (N=13) 
• Pre-symptomatic disease (6) 
• Pharmacogenetics (4) 
• Carrier status (3) 
10/15 UK Registered 
NB Companies may cover more than one type 
of testing
Excluded: 
Paternity testing (N=25) 
Ancestry (N=22) 
Neo-natal testing (N=1) 
Skincare (N=1) 
Biological ageing (N=1) 
Develop assessment checklist: 
Pilot assessment of 15 companies using 
HGC criteria 
Assessment of 15 companies:  
• Train independent assessors on assessment 
checklist 
• Assessment by three independent reviewers 
• Reconcile discordant results with fourth reviewer 
Study flow chart 
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Table 2. Illustration of the most and least frequently adhered-with principles. 
 
Most frequently specified: 
• Purchaser must verify that tissue sample is their own (12/15) [Surreptitious sampling]  
• That the company specified that informed consent is required for the testing service 
(12/15) [Specific Informed Consent Document] – see below section on consent for details 
• Specified duration of storage of the tissue samples (10/15) [Duration of storage] 
• Relevant data protection law applying to the service (9/15) [Data Protection] 
• Information on safeguards implemented to ensure data security (9/15) [Data security 
measures] 
NB the above criteria are also criteria mandated by various regulatory requirements and are 
required for company compliance and reduction of company liability. 
 
Least frequently specified: 
• No provider indicated the CE-mark on their webpage or mentioned its applicability to 
their service in the reviewed documents (0/15). [CE-marking] 
• No provider had explicit language around what genetic data would be generated, 
including limitations and accuracy of tests and specified that no further testing outside 
that scope would be conducted (0/15). [Accuracy and scope of testing] 
• Right to withdraw from the genetic testing service including specification of the 
consequences of withdrawal (e.g. data deletion, cost, access to stored information or 
future services) (1/15). [Right to withdraw from the service] (One provider stated “if you 
wish to stop using your account, you can do so at any time, you do not need to inform 
us”). 
• Consent to purchase genetic testing service is separated from consent to re-use of 
personal data for research (1/11)* [Service is independent of research] 
*Not applicable to companies stating that they do not share data for secondary purposes and 
tissue samples used for testing are destroyed afterwards. 



